# Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2

> **NIH NIH R01** · WASHINGTON UNIVERSITY · 2024 · $1,193,360

## Abstract

Project Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense single-stranded RNA virus
that was first isolated in Wuhan China in December, 2019. SARS-CoV-2 is the cause of coronavirus disease
2019 (COVID-19), which is now a pandemic and has caused more than 1.3 million confirmed cases and 72,000
deaths, with an estimated case fatality rate of 4%, with substantially higher death rates (~15%) in the elderly or
immunocompromised. Virtually all countries and territories have reported cases, with major epidemics in China,
Italy, Spain, France, Germany, Iran, and the United States. SARS-CoV-2 is thought to be of zoonotic origin, most
likely bats, and is about 75% identical to the original SARS-CoV. Most cases are spread by direct human-to-
human transmission, with community transmission in asymptomatic individuals described. Currently, no
countermeasures are licensed for human use. The development, characterization, and ultimately deployment of
an antibody-based treatment against SARS-CoV-2 could prevent substantial morbidity and mortality, and
possibly mitigate its epidemic spread. This interactive multi-PI proposal leverages complementary expertise in
the Diamond, Crowe, and Baric laboratories to rapidly develop highly neutralizing and therapeutic human
monoclonal antibodies (mAbs) against SARS-CoV-2 for immediate use in humans. To achieve this goal, we will
generate and interrogate human mAbs against SARS-CoV-2 that are obtained from multiple convalescent
subjects. We will identify potently neutralizing mAbs and optimize them for affinity by selecting naturally occurring
somatic variants identified by repertoire sequencing and sibling analysis and Fc effector functions. Protective
activity of top candidate coronavirus mAbs will be tested in newly-generated and optimized mouse models of
SARS-CoV-2 infection, including those expressing human ACE2 receptors (hACE2). To define correlates of
protection, we will use chimeric viruses, shotgun mutagenesis, and neutralization escape to identify the epitopes
of our most protective mAbs. Our team has extensive experience in the generation, characterization and
optimization of antibodies, CoV biology, and animal models of disease and protection. A therapy composed of
one to three highly neutralizing mAbs may provide an immediate countermeasure against the pandemic spread
of SARS-CoV-2 and help establish correlates of structural and functional humoral protection that ultimately
inform vaccine efforts.

## Key facts

- **NIH application ID:** 10902121
- **Project number:** 5R01AI157155-05
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Ralph S Baric
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,193,360
- **Award type:** 5
- **Project period:** 2020-09-15 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10902121

## Citation

> US National Institutes of Health, RePORTER application 10902121, Human antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2 (5R01AI157155-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10902121. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*